Sigma Healthcare Limited (ASX: SIG)
Sigma Healthcare Reshapes Operations Following Chemist Warehouse Integration
Sigma Healthcare Limited (ASX: SIG) recorded a period of transition for the twelve months ending 31 January 2025, marked by growing revenue and a major structural change. Total income reached $4.84 billion, representing a 45.7% lift from the prior year. Operational profit, excluding non-recurring items, came in at $68.0 million. After accounting for $46.3 million in costs related to one-off events, statutory profit before interest and tax stood at $21.7 million. The full-year result showed a net loss after tax of $13.8 million. Supply chain performance held steady, with consistent results across key metrics. Franchise pharmacy sales improved by 8.5%, while customer satisfaction indicators rose by 6.1%. Productivity in warehouse operations also advanced through automation and scale efficiencies.
The transaction combining Sigma Healthcare with Chemist Warehouse Group Holdings Limited reached completion on 12 February 2025, after receiving both shareholder support and legal clearance. The organisation also shifted its financial calendar to align with a new reporting cycle ending 30 June. From mid-2024, volume increases from Chemist Warehouse began contributing to distribution performance. A revised five-year agreement for community pharmacy took effect in January 2025, with financial contributions expected in later years. Cash at the end of the reporting period totalled $14.6 million. Earlier in the year, Sigma secured $400 million through a capital raise. It also entered into a $1.5 billion loan arrangement, replacing a previous facility. No final shareholder distribution was announced, keeping the full-year payout unchanged at 0.5 cents per share.
Nyrada Inc. (ASX: NYR)
Nyrada Progresses Clinical Program with Trial Milestones and Drug Efficacy Updates
Nyrada Inc. (ASX: NYR) continued advancing its clinical research during the March 2025 quarter, focusing on the development of NYR-BI03, its drug candidate aimed at both brain and heart protection. A clinical trial evaluating the drug in healthy participants is underway, testing how the compound behaves in the body and whether it is safe at various doses. Approvals allowed the study to expand into six groups, each testing different dose levels and infusion durations. By May 2025, the first three groups completed dosing with no safety issues reported, and dosing had commenced for the fourth. Lab studies showed promising signals: the drug helped reduce damage to the heart and brain in different models, with results showing less tissue damage and fewer abnormal cardiac patterns in test settings. Additional studies using models of stroke and traumatic brain injury reported protective results in brain tissue after treatment.
At the end of the quarter, Nyrada held $4.76 million in available cash. Operating outflows over the period were just under $1.0 million. Earlier in the year, the company boosted its funding position through share placements and government incentives. Development of NYR-BI03 is supported by an international patent filing that covers the compound's unique structure. The study is expected to conclude once all six groups have completed dosing, with outcomes anticipated later in 2025. Nyrada is continuing its focus on expanding research areas while moving forward with its trial timeline and reporting.
(Source: Company Announcements)
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
